<DOC>
	<DOCNO>NCT01748084</DOCNO>
	<brief_summary>The purpose study determine whether rituximab effective treatment articular symptom occur systemic sclerosis relate polyarthritis</brief_summary>
	<brief_title>Rituximab Systemic Sclerosis</brief_title>
	<detailed_description>Systemic sclerosis ( SSc ) rare disease , characterize microvascular immunological change promote extra-cellular matrix synthesis widespread fibrosis . No treatment yet prove ability alter disease fibrosing process . Specific auto-antibodies commonly find disease , B lymphocytes detect cutaneous pulmonary infiltrates . Studies derive murine model suggest role B lymphocyte block strategy . This lead observational trial B-cell therapy use rituximab SSc provide encouraging result particular signal concerning tolerability . These trial include heterogeneous patient variable disease stage different involved organ , mostly unblinded , preclude definitive conclusion . However , support continuous development therapeutic approach . Taking early phase diffuse form disease complicate rarity heterogeneous progression visceral complication . This raise question select homogeneous group patient evaluate . The convincing result use rituximab autoimmune condition find rheumatoid arthritis . Joint involvement common SSc 75 % patient complain joint stiffness pain , 30 % present synovitis , tenosynovitis , flexion contracture . No specific treatment already addressed issue , generally propose use small dose oral corticosteroid association methotrexate , analogy rheumatoid arthritis . We propose evaluate efficacy safety rituximab SSc patient active arthritis despite first line treatment . Improving articular involvement would improve quality life f SSc patient effectiveness rituximab skin lung fibrotic involvement assess secondary outcome estimate overall effect drug SSc .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Systemic sclerosis fulfil ACR LeRoy 's criterion Active polyarthritis define &gt; 6/53 tender joint &gt; 4/53 swollen joint Ongoing first line therapy prednisone ( max 10 mg/d ) DMARDS ( methotrexate , leflunomide , azathioprine mycophenolate ) Birth control applicable Overlap syndrome define clinical symptom positive specific autoantibody ( antiCCP , antiSSA , antiDNA DNA antiSm ) ( Rheumatoid factor antiRNP exclusion criterion ) Past therapy Rituximab . Severe uncontrolled disease renal , liver haematological ( neutropenia &lt; 1500 / mm3 ) failure , pulmonary ( FVC &lt; 50 % ) cardiac insufficiency ( LVEF &lt; 50 % ) Not stable corticosteroid therapy cyclophosphamide use last 6 month Infectious risk : viral infection B C hepatitis HIV , hypogammaglobulinemia ( &lt; 6 G/L ) , opportunistic infection infection require IV antibiotic last 3 month . Neoplastic solid tumor last 5 year Drug alcool abuse Receiving patient receive biotherapy ( antiTNF , abatacept tocilizumab ) last 3 month ( possible inclusion beyond 3 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Systemic sclerosis</keyword>
	<keyword>Arthritis</keyword>
	<keyword>B-cell therapy , Anti-CD20 therapy</keyword>
	<keyword>Quality life</keyword>
	<keyword>Scleroderma</keyword>
	<keyword>Lung fibrosis</keyword>
	<keyword>Randomised control trial</keyword>
</DOC>